Clinical Tumor Anemia Registry (TAR)
- Conditions
- Anemia
- Registration Number
- NCT01795690
- Lead Sponsor
- iOMEDICO AG
- Brief Summary
The purpose of this registry is to record information of routine treatment of anemia in cancer patients in Germany. An overview of the current treatment of anemia in German outpatient centers and hospitals will be provided. Primary outcome parameters, e.g. improvement in hemoglobin levels and changes in QoL, as well as patient characteristics of different treatments will be analyzed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1018
- Histologically confirmed malignant disease
- Hemoglobin level < 11 g/dl (female) or < 12 g/dl (male)
- Start of antianemic therapy no more than 7 days prior to informed consent
- Performance status 0 - 3 (Karnofsky-Index >= 40%)
- Minimum age: 18 years
- Informed written consent
- Hypersensitivity against antianemic therapies
- Myelodysplastic Syndrome
- Experimental antianemic therapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Documentation of therapies 12 weeks per patient Overview on the current routine treatment of anemia in cancer patients in Germany
- Secondary Outcome Measures
Name Time Method Change in hemoglobin levels and QoL 12 weeks per patient Effectiveness of different antianemic treatments is investigated by measuring increase of hemoglobin levels and QoL (FACT-An and FACT-GP).
Baseline in hemoglobin (before treatment) is compared with hemoglobin levels after treatment. Each patient is followed for a maximum of 12 weeks to obtain data about the course of the treatment.
Trial Locations
- Locations (1)
iOMEDICO
🇩🇪Freiburg, Germany